Sir,

Erythema multiforme (EM) has been rarely reported as a cutaneous manifestation of an underlying malignancy. We report a case of EM, the appearance of which coincided with systemic recurrence of breast cancer.

A 57 year old postmenopausal lady presented with an invasive ductal carcinoma in the right breast in January 2006. Clinical stage was T~4b~ N~3~ M~0~ (locally advanced). Immunohistochemistry was strongly positive for estrogen receptor, moderately positive for progesterone receptor and negative for HER2/neu. She was administered neoadjuvant chemotherapy with docetaxel-epirubicin combination for six cycles after which the tumor showed partial response and became operable. Then she underwent right-sided modified radical mastectomy. Residual tumor was identified in primary site and in seven out of nine resected axillary nodes. Thereafter she underwent locoregional radiotherapy, over 5 weeks, to the right chest-wall and supraclavicular fossa. She received tamoxifen 20 mg per day after surgery for 2 years, after which she was switched to letrozole. She took letrozole for 4 months and stopped on her own. After 4 months of discontinuing letrozole and three years from surgery, she presented with painful erythematous lesions on palms and soles interfering with her daily activities. There was no history of viral prodrome or intake of any other drug. Examination revealed well defined erythematous plaques on bilateral palms and soles with mild tenderness \[[Figure 1](#F1){ref-type="fig"}\]. Hemorrhagic bulla sized 3 cm × 3 cm was present on the right sole. Oral erosions were present on buccal mucosa and palate. Tzank smear from the oral erosions or bulla on the sole did not reveal multinucleate giant cells. Herpes serology for IgM and IgG was negative. A lesional skin biopsy was done, which was consistent with EM \[[Figure 2](#F2){ref-type="fig"}\].

![Well-defined erythematous plaques on both palms with yellow scaling in some areas](IJD-58-485-g001){#F1}

![Photomicrograph of skin biopsy showing inflammatory infiltrate at the dermo-epidermal junction (interface dermatitis) with vacuolization and destruction of the basal layer (H and E, original magnification ×100). Inset shows necrotic keratinocytes in the basal layer (arrows) (H and E, original magnification ×400)](IJD-58-485-g002){#F2}

The patient did not have any clinical signs or symptoms suggestive of a recurrence of breast cancer. An^18^ FDG PET-CT scan was done on clinical suspicion of EM, presenting as a paraneoplastic phenomenon. This showed multiple focal areas of increased uptake in liver and multiple bones, including multiple vertebrae, clavicle, many ribs, bilateral pelvic bones and femur. The scan was suggestive of active metastatic disease in the above mentioned sites. It appeared that EM could have been due to recurrence of breast cancer.

She was prescribed oral prednisolone, 30 mg per day, which resulted in the symptomatic improvement and flattening of the skin lesions. For the breast cancer recurrence, she was started on anastrozole 1 mg per day.

EM is usually a self-limited condition of the skin presumed to be due to hypersensitivity to certain infective agents (e.g., herpes simplex, mycoplasma) or drugs (e.g., barbiturates, phenytoin, non-steroidal anti-inflammatory drugs, and penicillin). EM has been reported to precede the diagnosis of extra-hepatic cholangiocarcinoma and renal cell cancer, with the courses of cutaneous and malignant disease running a parallel course. \[[@ref1][@ref2]\] EM like eruptions have been described in a patient of gastric adenocarcinoma with generalized prurigo simplex of two years duration. \[[@ref3]\] A paraneoplastic syndrome mimicking adult-onset Still\'s disease has been reported as a manifestation of breast cancer where the rash resembled EM. \[[@ref4]\] EM can also occur after chemotherapy with paclitaxel, or radiotherapy in conjunction with the aromatase inhibitor anastrozole. \[[@ref5]\] To the best of our knowledge, this is the first report of EM as a paraneoplastic cutaneous manifestation of breast cancer. Our case illustrates the fact, that sudden appearance of EM in a known case of malignancy can herald systemic cancer recurrence, and in such cases an extensive evaluation to rule out the same may be worthwhile.
